Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Safeguarding America's Pharmaceuticals Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Supply chain safety (H.R. 1919, S. 959, S. 957)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
MERCK & CO INC via MERCK & CO, INC.
2013 · first_quarter · 1A
Deficit reduction (no specific bill); ADAP funding (no specific bill)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); US-EU trade agreement (no specific bill); trade promotion authority (no specific bill)
Source: Senate LDA
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Supply chain safety (H.R. 1919, S. 959, S. 957)
Pharmaceutical Quality, Security, and Accountability Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Supply chain safety (H.R. 1919, S. 959, S. 957)
Generating Antibiotic Incentives Now Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Reauthorization of the Prescription Drug User Fee Act (H.R. 5651; S. 3187); incentives for antibiotic research and development (H.R. 2182; H.R. 5651; S. 3187); hepatitis C education (no specific bill); improvements to vaccine immunization (no specific bill); 340b (no specific bill).
Generating Antibiotic Incentives Now Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Reauthorization of the Prescription Drug User Fee Act (H.R. 5651; S. 3187); incentives for antibiotic research and development (H.R. 2182; H.R. 5651; S. 3187); hepatitis C education (H.R. 3381); improvements to vaccine immunization (no specific bill); 340b (no specific bill).
Generating Antibiotic Incentives Now Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Prescription Drug User Fee Act (no specific bill); incentives for antibiotic research and development (H.R. 2182); hepatitis C education (no specific bill); improvements to vaccine immunization (no specific bill); 340b (no specific bill)
Preserving Access to Life-Saving Medications Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Supply chain safety (no specific bill); pharmaceutical shortages (H.R. 2245, S. 296)
Preserving Access to Life-Saving Medications Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187)
Preserving Access to Life-Saving Medications Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187; H.R. 3381)
Preserving Access to Life-Saving Medications Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187; H.R. 3381)
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187; H.R. 3381)
Reauthorization of the Prescription Drug User Fee Act (H.R. 5651; S. 3187); incentives for antibiotic research and development (H.R. 2182; H.R. 5651; S. 3187); hepatitis C education (H.R. 3381); improvements to vaccine immunization (no specific bill); 340b (no specific bill).
Hepatitis C education (H.R. 3381); Alzheimer's education (no specific bill); improvements to vaccine immunization (no specific bill); 340b (no specific bill).
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187; H.R. 3381)
Medicare Decisions Accountability Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
Medicare Decisions Accountability Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
Medicare Decisions Accountability Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
Medicare Decisions Accountability Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
Food and Drug Administration Reform Act of 2012
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187)
Food and Drug Administration Reform Act of 2012
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Reauthorization of the Prescription Drug User Fee Act (H.R. 5651; S. 3187); incentives for antibiotic research and development (H.R. 2182; H.R. 5651; S. 3187); hepatitis C education (H.R. 3381); improvements to vaccine immunization (no specific bill); 340b (no specific bill).
Food and Drug Administration Reform Act of 2012
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Reauthorization of the Prescription Drug User Fee Act (H.R. 5651; S. 3187); incentives for antibiotic research and development (H.R. 2182; H.R. 5651; S. 3187); hepatitis C education (no specific bill); improvements to vaccine immunization (no specific bill); 340b (no specific bill).
Food and Drug Administration Reform Act of 2012
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187; H.R. 3381)
Food and Drug Administration Reform Act of 2012
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187; H.R. 3381)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
Generating Antibiotic Incentives Now Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Prescription Drug User Fee Act (no specific bill); importation of pharmaceuticals (no specific bill); incentives for antibiotic research and devlopment (H.R. 2182); hepatitis C education (no specific bill); pharmaceutical shortages (S. 296, HR. 2245)
Generating Antibiotic Incentives Now Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Prescription Drug User Fee Act (no specific bill); importation of pharmaceuticals (no specific bill); incentives for antibiotic research and development (H.R. 2182); hepatitis C education (no specific bill); pharmaceutical shortages (S. 296, H.R. 2245)
Generating Antibiotic Incentives Now Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Prescription Drug User Fee Act reauthorization (no specific bill); importation of pharmaceuticals (no specific bill); incentives for antibiotic research and development (H.R. 2182); hepatitis C education (no specific bill); improvements to immunizations (no specific bills); health literacy (no specific bills); adherence (no specific bill)
Preserving Access to Life-Saving Medications Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Prescription Drug User Fee Act (no specific bill); importation of pharmaceuticals (no specific bill); incentives for antibiotic research and development (H.R. 2182); hepatitis C education (no specific bill); pharmaceutical shortages (S. 296, H.R. 2245)
Preserving Access to Life-Saving Medications Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Prescription Drug User Fee Act (no specific bill); importation of pharmaceuticals (no specific bill); incentives for antibiotic research and devlopment (H.R. 2182); hepatitis C education (no specific bill); pharmaceutical shortages (S. 296, HR. 2245)
United States-Korea Free Trade Agreement Implementation Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Korea Free Trade Agreement (H.R. 3080); TranPacific Partnership
Medicare Decisions Accountability Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, S. 668)
Medicare Decisions Accountability Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, S. 668)
Medicare Decisions Accountability Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, S. 668)
Medicare Decisions Accountability Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, S. 668)
American Research and Competitiveness Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); renewal and expansion of the R&D tax credit (H.R. 942); repatriation (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income.
American Research and Competitiveness Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); renewal and expansion of teh R&D tax credit (H.R. 942); repatriation (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill).
American Research and Competitiveness Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); renewal and expansion of the R&D tax credit (H.R. 942; S 1577); repatriation (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill).
American Research and Competitiveness Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); renewal and expansion of the R&D tax credit (H.R. 942); repatriation (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill).
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Patent settlements (no specific bill)
Alzheimer's education (no specific bill); 340b (no specific bill); hepatitis C education (no specific bill).
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill).
Supply chain safety (no specific bills)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO INC via MERCK & CO, INC.
2013 · third_quarter · Q3
Alzheimer's education (no specific bill); 340b (no specific bill); maternal health education (no specific bill).
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
MERCK & CO INC via MERCK & CO, INC.
2013 · second_quarter · Q2
Supply chain safety (H.R. 1919, S. 959, S. 957)
Patent settlements (no specific bill)
Alzheimer's education (no specific bill); 340b (no specific bill); maternal health education (no specific bill).
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); US-EU trade agreement (no specific bill); trade promotion authority (no specific bill); treatment of intellectual property in India (no specific bill); additives in beef cattle (no specific bill); treatment of intellectual property in India
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill).
Access to over-the-counter medications (no specific bill); compounding (no specific bill)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Deficit reduction (no specific bill); ADAP funding (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
MERCK & CO INC via MERCK & CO, INC.
2013 · first_quarter · Q1
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill).
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Alzheimer's education (no specific bill); 340b (no specific bill); hepatitis C education (no specific bill).
Patent settlements (no specific bill)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); US-EU trade agreement (no specific bill); trade promotion authority (no specific bill)
Deficit reduction (no specific bill); ADAP funding (no specific bill)
Supply chain safety (no specific bills)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO INC via MERCK & CO, INC.
2012 · fourth_quarter · Q4
Deficit reduction (no specific bill); ADAP funding (no specific bill)
Hepatitis C education (H.R. 3381); Alzheimer's education (no specific bill); improvements to vaccine immunization (no specific bill); 340b (no specific bill).
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill).
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187; H.R. 3381)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); permanent normal trade relations with Russia (no specific bill); non-tariff trade barriers on U.S. beef (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO INC via MERCK & CO, INC.
2012 · third_quarter · Q3
Reauthorization of the Prescription Drug User Fee Act (H.R. 5651; S. 3187); incentives for antibiotic research and development (H.R. 2182; H.R. 5651; S. 3187); hepatitis C education (H.R. 3381); improvements to vaccine immunization (no specific bill); 340b (no specific bill).
Deficit reduction (no specific bill); ADAP funding (no specific bill)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
MERCK & CO INC via MERCK & CO, INC.
2012 · second_quarter · Q2
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); permanent normal trade relations with Russia (no specific bill); non-tariff trade barriers on U.S. beef (no specific bill)
Reauthorization of the Prescription Drug User Fee Act (H.R. 5651; S. 3187); incentives for antibiotic research and development (H.R. 2182; H.R. 5651; S. 3187); hepatitis C education (no specific bill); improvements to vaccine immunization (no specific bill); 340b (no specific bill).
MERCK & CO INC via MERCK & CO, INC.
2012 · first_quarter · Q1
Supply chain safety (no specific bill); pharmaceutical shortages (H.R. 2245, S. 296)
Comprehensive Tax Reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
MERCK & CO INC via MERCK & CO, INC.
2011 · fourth_quarter · Q4
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, S. 668)
Korea Free Trade Agreement (H.R. 3080); TranPacific Partnership
Deficit Reduction (no specific bill)
MERCK & CO INC via MERCK & CO, INC.
2011 · third_quarter · Q3
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, S. 668)
Prescription Drug User Fee Act (no specific bill); importation of pharmaceuticals (no specific bill); incentives for antibiotic research and development (H.R. 2182); hepatitis C education (no specific bill); pharmaceutical shortages (S. 296, H.R. 2245)
Patent Reform (H.R. 1249)
MERCK & CO INC via MERCK & CO, INC.
2011 · second_quarter · Q2
Deficit reduction (no specific bill); WTO Cotton agreement (H.R. 2112); FDA funding (H.R. 2112); ADAP funding (no specific bill)
Prescription Drug User Fee Act (no specific bill); importation of pharmaceuticals (no specific bill); incentives for antibiotic research and devlopment (H.R. 2182); hepatitis C education (no specific bill); pharmaceutical shortages (S. 296, HR. 2245)
Patent Reform (H.R. 1249)
MERCK & CO INC via MERCK & CO, INC.
2011 · first_quarter · Q1
Prescription Drug User Fee Act (no specific bill); importation of pharmaceuticals (no specific bill).
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, S. 668)
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); renewal and expansion of the R&D tax credit (H.R. 942); repatriation (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income.
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill).
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); permanent normal trade relations with Russia (no specific bill); non-tariff trade barriers on U.S. beef (no specific bill)
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187; H.R. 3381)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Prescription Drug User Fee Act (no specific bill); incentives for antibiotic research and development (H.R. 2182); hepatitis C education (no specific bill); improvements to vaccine immunization (no specific bill); 340b (no specific bill)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); non-tariff trade barriers on U.S. beef
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); renewal and expansion of the R&D tax credit (H.R. 942; S 1577); repatriation (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill).
Prescription Drug User Fee Act reauthorization (no specific bill); importation of pharmaceuticals (no specific bill); incentives for antibiotic research and development (H.R. 2182); hepatitis C education (no specific bill); improvements to immunizations (no specific bills); health literacy (no specific bills); adherence (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Deficit Reduction (no specific bill); WTO Cotton Agreement (H.R. 2112)
Korea, Panama and Colombia Free Trade Agreements (no specifc bills); TransPacific Partnership
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); renewal and expansion of teh R&D tax credit (H.R. 942); repatriation (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Korea, Colombia and Panama Free Trade Agreements (no specific bills); data exclusivity in free trade agrements (no specific bills)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, S. 668)
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); renewal and expansion of the R&D tax credit (H.R. 942); repatriation (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Supplemental examination (S. 23)
Deficit reduction (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE